Shots:
- Teva has launched Ahzantive, a biosimilar version of Eylea, in EU, with pre-filled syringe launches beginning in May 2026 in France, Germany, Spain, & the Netherlands, and additional market launches planned later in 2026
- Ahzantive received EC approval in 2025 for the treatment of wet age-related macular degeneration, diabetic macular edema, visual impairment due to myopic choroidal neovascularization, and macular edema following retinal vein occlusion
- The launch follows Teva’s semi-exclusive commercialization agreement with Klinge Biopharma & Formycon, further expanding the company’s biosimilars portfolio & presence in the ophthalmology market
Ref: Teva | Image: Teva | Press Release
Related News: Teva to Acquire Emalex Biosciences for ~$900M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
